# Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

> **NCT00612417** · PHASE1 · COMPLETED · sponsor: **ThromboGenics** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402

## Key facts

- **NCT ID:** NCT00612417
- **Lead sponsor:** ThromboGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612417, "Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00612417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*